Shalby

Shalby FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Shalby (SHALBY.NS) as of Oct 20, 2026 is -487.85 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -1,651.35 % — a change of -70.46% (higher).

FCF Conversion

-487.85 %

YoY

-70.46%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Shalby is 2026 -487.85 % . FCF Conversion Rate (FCF/EBITDA) of Shalby was 2025 -1,651.35 % . It decreases by -70.46% higher compared to the previous year.

The Shalby FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
9.01 INR
Jan 1, 2020
129.06 INR
Jan 1, 2021
136.31 INR
Jan 1, 2022
-104.35 INR
Jan 1, 2023
72.81 INR
Jan 1, 2024
-32.72 INR
Jan 1, 2025
-1,651.35 INR
Jan 1, 2026
-487.85 INR
The Shalby FCF Conversion history
YEARFCF ConversionYoY
-487.85 %-70.46%
-1,651.35 %+4,946.73%
-32.72 %-144.94%
72.81 %-169.77%
-104.35 %-176.55%
136.31 %+5.61%
129.06 %+1,332.28%
9.01 %-103.11%
-289.88 %+103.87%
-142.19 %-43.49%
-251.63 %-208.27%
232.42 %-507.59%
-57.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shalby Stock analysis

What does Shalby do? Shalby Ltd operates hospitals and outpatient clinics in Ahmedabad, Gujarat, with 2,678 full-time employees. The company generates revenue through its Healthcare Services segment, which includes managing hospitals and medical diagnostic services, and its Manufacturing segment focused on producing implants. Key specialties driving demand include joint replacement surgery, critical care, spine surgery, neurology, cardiology, and organ transplants such as kidney and liver procedures. Patients seeking specialized treatments, including ortho-oncology, IVF, and bariatric surgery, form the primary customer base for its healthcare services. The firm's manufacturing division produces medical implants, serving hospitals and clinics under its own brand. Services like homecare, dental cosmetics, and ophthalmology cater to a diverse patient demographic. Revenue streams are derived from both direct patient care and the supply of implants to its own facilities, with no external brands or partnerships mentioned in the business description. Shalby Ltd's business model relies on integrated healthcare delivery across multiple specialties, combining hospital management, diagnostic services, and implant manufacturing. The company's focus on high-demand medical procedures ensures consistent patient flow, while its manufacturing segment supports internal operations without external sales. All services are provided within its owned facilities, emphasizing a vertically integrated approach to healthcare delivery. Shalby is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shalby stock

FCF Conversion Rate (FCF/EBITDA) of Shalby is -487.85 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Shalby changed from -1,651.35 % to -487.85 %, representing a -70.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Shalby since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Shalby with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Shalby

All Key Metrics — Shalby